2005
DOI: 10.1016/j.athoracsur.2004.03.072
|View full text |Cite
|
Sign up to set email alerts
|

Forty Years of Clinical Aprotinin Use: A Review of 124 Hypersensitivity Reactions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
53
0
3

Year Published

2007
2007
2018
2018

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 104 publications
(57 citation statements)
references
References 50 publications
0
53
0
3
Order By: Relevance
“…Eleven patients died. The re-exposure interval was <3 months in 72% (38 of 53 patients) (203). However, anaphylaxis upon first exposure as been described (203,204).…”
Section: Aprotininmentioning
confidence: 99%
See 2 more Smart Citations
“…Eleven patients died. The re-exposure interval was <3 months in 72% (38 of 53 patients) (203). However, anaphylaxis upon first exposure as been described (203,204).…”
Section: Aprotininmentioning
confidence: 99%
“…The re-exposure interval was <3 months in 72% (38 of 53 patients) (203). However, anaphylaxis upon first exposure as been described (203,204). Anaphylaxis from aprotinin can result from intravenous administration as well as topical exposure (e.g.…”
Section: Aprotininmentioning
confidence: 99%
See 1 more Smart Citation
“…This is a bovine-derived protease inhibitor used via the parenteral route as a fibrinolysis inhibitor or topically as a surgical glue [17]. The incidence of reactions in cardiac surgery is 0.5% but it can increase to 2.5-2.8% in patients who have previously undergone multiple surgeries [99,100], especially in the previous six months [31]. Perioperative anaphylaxis has also occurred upon the first parenteral administration in patients that had previously received topical aprotinin [17].…”
Section: B) High Molecular Weight Agentsmentioning
confidence: 99%
“…Παροµοίως, κάποιοι από τους τοπικούς παράγοντες περιέχουν απροτινίνη, ειδικά αυτοί που κατασκευάζονται στην Ευρώπη. Η χρήση της απροτινίνης στους τοπικούς αιµοστατικούς παράγοντες ενέχει το δυνητικό κίνδυνο της ευαισθητοποίησης των ασθενών σε αυτό τον παράγοντα και η ακόλουθη επανέκθεση στην απροτινίνη, ειδικά εντός 6 µηνών από την αρχική δόση, εµφανίζει 5% συχνότητα εµφάνισης αντίδραση υπερευαισθησίας, κυρίως αναφυλαξία [750,751]. Εξαιτίας της µη αναγνωρισµένης προηγούµενης έκθεσης στην απροτινίνη, η ανάπτυξη ενός προσεκτικού ιστορικού φαρµακευτικής αγωγής και άλλων προληπτικών µέτρων είναι ουσιαστικά πριν τη χρήση της απροτινίνης για διατήρηση αίµατος [752].…”
Section: η αορτοστεφανιαία παράκαµψη µε πάλλουσα καρδιά (Opcab) είναιunclassified